Paras Abbas

Clinical Oncologist
Making cancer care kinder, brighter, better

[Mark Lewis, MD, FASCO @marklewismd]

A p-value with a double-digit negative exponent is such an incredible (and richly deserved) flex #ASCO26

[Jeff Ryckman @jryckman3]

Desmoid tumors are rare, locally aggressive soft tissue tumors driven by Wnt pathway mutations. Importantly, they have zero metastatic potential

Even better: 50-60% eventually stop growing on their own and 20-30% regress spontaneously

A multi-disciplinary thread. Let's dig in!

[Entisar saleh @Entisar_kilani]

Endometrial cancer molecular staging .

#Oncology #medtwitter #endometrial

[Yakup Ergün @dr_yakupergun]

Algorithm for Systemic Therapy in HER2-Positive Breast Cancer

(Based on NCCN and ESMO guidelines; recommendations in gray areas reflect the St. Gallen 2025 consensus and, in part, my own clinical judgment)

[Entisar saleh @Entisar_kilani]

Endometrial cancer guidelines summary
#oncology #medrwitter

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🇫🇷🧬 Gastric cancer: updated French guidelines (2026)

🔹 Periop FLOT = SoC ≥cT2/cN+
🔹 + Durva → PFS & OS benefit
🔹 M1 setting → biomarker-driven (HER2, CLDN18.2, MSI, PD-L1)
🔹 MDT & staging key (incl. laparoscopy)

📌 Increasingly precision-based management

🔗 https://t.co/ojc099qibt
@OncoAlert

[Oncology Brothers @OncBrothers]

This is the current treatment landscape and recent data around HERIZON-GEA-01 for Her2 GEJ/Gastric Cancer that we touched on with @SunnieSKim and @Sam_Cytryn

#OncTwitter #Oncology #gism @gotoPER

[Enrique Grande @drenriquegrande]

⚡️ New SITC clinical practice guideline (v3.0) on immunotherapy in RCC: practical recommendations across adjuvant + metastatic settings, special populations, response monitoring, and QoL.

Key reminders: PD-L1/TMB/MSI don’t guide selection; sarcomatoid features favor IO—nivo/ipi remains a preferred option.

#KidneyCancer #RCC @crisbergerot
@OncoAlert

https://t.co/oDPnQzWxK8

[Thor Halfdanarson @OncoThor]

Time for another NET talk - this time on sequencing of systemic therapy. Another excellent @MayoMedEd offering. If you are looking for a good course in pretty much anything in Med Ed, check them out. They have a huge selection of quality courses, not just in oncology.

So how to we select initial therapy for advanced NETs when resection or other regional therapy is not a good option...? Below are some thoughts, as always open to criticism and and comments (snarky comments also welcomed if you feel so inclined...).

Come join us for future Mayo Clinic conferences!

[Nieves Martinez Lago MD PhD @DraMartinezLago]

📣@GgnetGrupo PRRT consensus in NETs is published!

✔️ PRRT for progressive SSTR+ GEP-NETs (G1–G3, Ki-67 ≤55%)
📌 SSTR-PET essential for patient selection
🔎 FDG-PET adds prognostic value
🎯 Practical guidance to harmonize PRRT selection, treatment and follow-up

Proud to lead this work!

🔗 https://t.co/HstbZihNch
@OncoAlert

[Kate Sears @MedwatchKate]

What happened this week in #BreastCancer:

1️⃣ Practice-changing data in high-risk HER2+ early-stage disease are sharpening decision points around neoadjuvant regimen selection and toxicity trade-offs, increasing demand for clear sequencing guidance and trial-informed counseling.
https://t.co/yCvz2enYNk

[CarlottaB @CarlottaB]

Radiotherapy–drug combinations need to move earlier in the development pipeline to truly maximise patient benefit. Check the new ESTRO Focus Group Policy Review. Read the full article: https://t.co/D1SQyBlkDz
#ESTRO #Radiotherapy #RadOnc #OncoTwitter 📄🎯

[Entisar saleh @Entisar_kilani]

Simplified approach to uterine carcinoma.

#MedTwitter #Oncology #OncoDaily

[Paras Abbas @dotdatd]

Post neo-adjuvant trastuzumab deruxtecan demonstrated a significant improvement in invasive diseases free survival compared to transtuzumab emtansine
.3 years invasive DFS: 92.4% v/s 83.7%
.HR 0.47(p< 0.001)
However interpretation must be carefully balance efficacy with toxicity

[Entisar saleh @Entisar_kilani]

Simplified classification and diagnostic algorithm for PTCL

#MedTwitter #oncology #Hematology

[Anirban Maitra @Aiims1742]

Two papers in @CR_AACR highlighting the unique biology of KRASG12R allele in #PancreaticCancer:
(A) weaker MAPK activation leading to greater MAPKi sensitivity
https://t.co/dBn3WaTdLt
(B) PTEN oxidation dependent (and KRAS independent) PI3K activation
https://t.co/r6BjIoHgJQ

[Prof Lennart Nacke, PhD @acagamic]

Example of how to structure a literature review

[Paras Abbas @dotdatd]

The best way to support others is not to cheer them up. It's to show up

[Luis Moreno Sánchez @radioncoluis]

Recent developments in the field of radiotherapy for the management of lung cancer.

https://t.co/uHEIgHy9xM.

[Yakup Ergün @dr_yakupergun]

#ESMO24

HR+/HER2- Breast Cancer Treatment Guideline (@myESMO Pocket Guideline)